Kisspeptin as a marker for male infertility: a comparative study of serum and seminal plasma kisspeptin between fertile and infertile men.

IF 2.7 3区医学 Q2 GENETICS & HEREDITY

Journal of Assisted Reproduction and Genetics Pub Date : 2025-09-11 DOI:10.1007/s10815-025-03644-w

Nichamon Parkpinyo, Sirichet Anekpornwattana, Chantacha Sitticharoon, Somsin Petyim

{"title":"Kisspeptin as a marker for male infertility: a comparative study of serum and seminal plasma kisspeptin between fertile and infertile men.","authors":"Nichamon Parkpinyo, Sirichet Anekpornwattana, Chantacha Sitticharoon, Somsin Petyim","doi":"10.1007/s10815-025-03644-w","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to identify kisspeptin as a new marker for infertility in men with abnormal semen parameters by comparing serum and seminal plasma kisspeptin levels between fertile men and infertile men with normal and abnormal semen parameters.Methods: Fertile men (group A), infertile men with normal semen parameters (group B), and infertile men with abnormal semen parameters (group C) were recruited. Fasting venous blood was tested for kisspeptin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, insulin-like growth factor 1 (IGF-1), insulin, and glucose. Semen was collected by self-masturbation, and semen analysis was performed, then was tested for kisspeptin and testosterone.Results: Fifty-two men were included in the study (17 fertile men in group A, 18 infertile men in group B, and 17 infertile men in group C). Serum kisspeptin levels were significantly lower in fertile men (group A) as compared to infertile men (groups B and C) regardless to semen parameters (85.18 ± 20.47 ng/dL, 109.37 ± 28.64 ng/dL, and 108.70 ± 32.30 ng/dL respectively; p = 0.019). While seminal plasma kisspeptin levels were not significantly different (245.95 ± 67.12 ng/dL, 283.73 ± 119.82 ng/dL, and 312.99 ± 245.17 ng/dL, respectively; p = 0.48). There was no significant difference among groups for serum FSH, LH, testosterone, IGF-1, fasting insulin, fasting glucose, homeostasis model assessment of insulin resistance (HOMA-IR), and seminal plasma testosterone.Conclusion: Serum kisspeptin might be used as a more sensitive marker for male infertility rather than FSH and LH. However, the clinical application of kisspeptin in the treatment of male infertility requires further study.","PeriodicalId":15246,"journal":{"name":"Journal of Assisted Reproduction and Genetics","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Assisted Reproduction and Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10815-025-03644-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to identify kisspeptin as a new marker for infertility in men with abnormal semen parameters by comparing serum and seminal plasma kisspeptin levels between fertile men and infertile men with normal and abnormal semen parameters.

Methods: Fertile men (group A), infertile men with normal semen parameters (group B), and infertile men with abnormal semen parameters (group C) were recruited. Fasting venous blood was tested for kisspeptin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, insulin-like growth factor 1 (IGF-1), insulin, and glucose. Semen was collected by self-masturbation, and semen analysis was performed, then was tested for kisspeptin and testosterone.

Results: Fifty-two men were included in the study (17 fertile men in group A, 18 infertile men in group B, and 17 infertile men in group C). Serum kisspeptin levels were significantly lower in fertile men (group A) as compared to infertile men (groups B and C) regardless to semen parameters (85.18 ± 20.47 ng/dL, 109.37 ± 28.64 ng/dL, and 108.70 ± 32.30 ng/dL respectively; p = 0.019). While seminal plasma kisspeptin levels were not significantly different (245.95 ± 67.12 ng/dL, 283.73 ± 119.82 ng/dL, and 312.99 ± 245.17 ng/dL, respectively; p = 0.48). There was no significant difference among groups for serum FSH, LH, testosterone, IGF-1, fasting insulin, fasting glucose, homeostasis model assessment of insulin resistance (HOMA-IR), and seminal plasma testosterone.

Conclusion: Serum kisspeptin might be used as a more sensitive marker for male infertility rather than FSH and LH. However, the clinical application of kisspeptin in the treatment of male infertility requires further study.

查看原文本刊更多论文

Kisspeptin作为男性不育的标志物：可育男性和不育男性血清和精浆Kisspeptin的比较研究。

目的：本研究旨在通过比较精液参数正常与异常的可育男性与不育男性血清和精浆中kisspeptin水平，确定kisspeptin作为精液参数异常男性不孕症的新标志物。方法：招募有生育能力的男性（A组）、精液参数正常的不育男性（B组）和精液参数异常的不育男性（C组）。空腹静脉血检测kisspeptin、促卵泡激素（FSH）、促黄体生成素（LH）、睾酮、胰岛素样生长因子1 （IGF-1）、胰岛素和葡萄糖。自撸采集精液，进行精液分析，检测kisspeptin和睾酮水平。结果：52名男性被纳入研究（A组17名有生育能力的男性，B组18名有生育能力的男性，C组17名有生育能力的男性）。不论精液参数如何，可育男性（A组）血清kisspeptin水平均显著低于不育男性（B组和C组）（分别为85.18±20.47 ng/dL、109.37±28.64 ng/dL和108.70±32.30 ng/dL, p = 0.019）。而精浆kisspeptin水平差异无统计学意义（分别为245.95±67.12 ng/dL、283.73±119.82 ng/dL和312.99±245.17 ng/dL, p = 0.48）。各组间血清FSH、LH、睾酮、IGF-1、空腹胰岛素、空腹血糖、胰岛素抵抗稳态模型评估（HOMA-IR）和精浆睾酮无显著差异。结论：血清kisspeptin可作为男性不育较FSH和LH更敏感的指标。但kisspeptin在男性不育治疗中的临床应用还有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Assisted Reproduction and Genetics 医学-妇产科学

CiteScore

5.70

自引率

9.70%

发文量

286

审稿时长

1 months

期刊介绍： The Journal of Assisted Reproduction and Genetics publishes cellular, molecular, genetic, and epigenetic discoveries advancing our understanding of the biology and underlying mechanisms from gametogenesis to offspring health. Special emphasis is placed on the practice and evolution of assisted reproduction technologies (ARTs) with reference to the diagnosis and management of diseases affecting fertility. Our goal is to educate our readership in the translation of basic and clinical discoveries made from human or relevant animal models to the safe and efficacious practice of human ARTs. The scientific rigor and ethical standards embraced by the JARG editorial team ensures a broad international base of expertise guiding the marriage of contemporary clinical research paradigms with basic science discovery. JARG publishes original papers, minireviews, case reports, and opinion pieces often combined into special topic issues that will educate clinicians and scientists with interests in the mechanisms of human development that bear on the treatment of infertility and emerging innovations in human ARTs. The guiding principles of male and female reproductive health impacting pre- and post-conceptional viability and developmental potential are emphasized within the purview of human reproductive health in current and future generations of our species. The journal is published in cooperation with the American Society for Reproductive Medicine, an organization of more than 8,000 physicians, researchers, nurses, technicians and other professionals dedicated to advancing knowledge and expertise in reproductive biology.